Related Experiment Video

Updated: Apr 25, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.1K

EFA6B antagonizes breast cancer

Joséphine Zangari1, Mariagrazia Partisani1, François Bertucci2

  • 1Institut de Pharmacologie Moléculaire et Cellulaire, Université de Nice Sophia-Antipolis CNRS UMR7275, Valbonne, France.

Cancer Research
|August 14, 2014
PubMed

Insights

EFA6B protein is crucial for maintaining epithelial cell structure and polarity. Its reduced expression in breast cancer is linked to aggressive tumor subtypes and poor prognosis, suggesting EFA6B as a potential therapeutic target.

Area of Science:

  • Cell Biology
  • Cancer Research
  • Molecular Biology

Background:

  • Epithelial carcinogenesis involves loss of tight junctions and cell polarity, disrupting barrier function.
  • Epithelial-mesenchymal transition (EMT) is a key process in cancer progression and metastasis.
  • Arf6-interacting protein EFA6B plays a role in cell structure and polarity.

Purpose of the Study:

  • To investigate the role of EFA6B in maintaining epithelial cell polarity and its association with breast cancer progression.
  • To determine if EFA6B expression levels correlate with epithelial-mesenchymal status and breast cancer subtypes.

Main Methods:

  • Organotypic three-dimensional cell cultures to assess epithelial-mesenchymal status.
  • Analysis of EFA6B expression in human breast tumors using transcriptomic and immunohistochemical methods.
  • Correlation analysis between EFA6B levels, tight junction components, EMT signatures, and cancer stemness.

Main Results:

  • EFA6B is essential for maintaining apico-basal cell polarity and epithelial phenotype in mammary cells.
  • Downregulation of EFA6B promotes mesenchymal phenotypes and epithelial-to-mesenchymal transition (EMT).
  • Reduced EFA6B expression in human breast tumors correlates with loss of tight junctions, increased EMT and stemness signatures, and poor prognosis, particularly in triple-negative and claudin-low subtypes.

Conclusions:

  • EFA6B acts as a novel antagonist in breast cancer progression.
  • EFA6B's regulatory and signaling pathways represent potential therapeutic targets for aggressive breast cancers.
  • Maintaining EFA6B expression may be critical for preventing EMT and improving patient outcomes.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.7K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
1.8K